The Nutritional Outlook Podcast Episode 8: Which ingredients should you watch in 2022?

Trade groups say the law's broad criteria could restrict access to supplements with uses beyond weight loss or muscle building.

At The Outlook on Active Nutrition, Doug Kalman, PhD, RD, FISSN, outlines where GLP-1 drugs are falling short, and where nutraceutical brands can step in.

At The Outlook on Active Nutrition, Michelle Arent, RD, MPH, CSCS, CISSN, director of Olympic sports performance nutrition at the University of South Carolina, tells attendees that vague testing language is putting college athletes at risk, and called on supplement brands to build clearer, more transparent partnerships with universities and practitioners.

The retail commercialization firm outlines its post-event strategy for emerging and international wellness brands entering the U.S. market, following the ECRM Vitamin, Weight Management & Sports Nutrition Session.

In the ninth episode, Nicholas and Lana unpack several longevity launches making waves, and why regulatory clearance, novelty, and clinical data are 3 separate things brands shouldn't blur together.

Part 2 of our interview with Todd Harrison, co-chair of the FDA practice group at Venable LLP covers preclusion's structural gaps: no defined end point, no tracking registry, and a push for mandatory drug-sponsor engagement.

Todd Harrison, co-chair of the FDA practice group at Venable LLP, details the Dietary Supplement Innovation Act's language, its unintended consequences, and what industry stakeholders should watch for.

The company's newest chewable concepts pair postbiotics with biotin and vitamin D3 to support skin, hair, and immune health.